Please use this identifier to cite or link to this item:
|Title:||Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction||Authors:||Clegg, H.V.
|Issue Date:||29-May-2012||Citation:||Clegg, H.V., Itahana, Y., Itahana, K., Ramalingam, S., Zhang, Y. (2012-05-29). Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction. PLoS ONE 7 (5) : -. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0038212||Abstract:||The p53 transcription factor and tumor suppressor is regulated primarily by the E3 ubiquitin ligase Mdm2, which ubiquitinates p53 to target it for proteasomal degradation. Aside from its ubiquitin ligase function, Mdm2 has been believed to be capable of suppressing p53's transcriptional activity by binding with and masking the transactivation domain of p53. The ability of Mdm2 to restrain p53 activity by binding alone, without ubiquitination, was challenged by a 2007 study using a knockin mouse harboring a single cysteine-to-alanine point mutation (C462A) in Mdm2's RING domain. Mouse embryonic fibroblasts with this mutation, which abrogates Mdm2's E3 ubiquitin ligase activity without affecting its ability to bind with p53, were unable to suppress p53 activity. In this study, we utilized the Mdm2C462A mouse model to characterize in further detail the role of Mdm2's RING domain in the control of p53. Here, we show in vivo that the Mdm2C462A protein not only fails to suppress p53, but compared to the complete absence of Mdm2, Mdm2C462A actually enhances p53 transcriptional activity toward p53 target genes p21/CDKN1A, MDM2, BAX, NOXA, and 14-3-3σ. In addition, we found that Mdm2C462A facilitates the interaction between p53 and the acetyltransferase CBP/p300, and it fails to heterodimerize with its homolog and sister regulator of p53, Mdmx, suggesting that a fully intact RING domain is required for Mdm2's inhibition of the p300-p53 interaction and for its interaction with Mdmx. These findings help us to better understand the complex regulation of the Mdm2-p53 pathway and have important implications for chemotherapeutic agents targeting Mdm2, as they suggest that inhibition of Mdm2's E3 ubiquitin ligase activity may be sufficient for increasing p53 activity in vivo, without the need to block Mdm2-p53 binding. © 2012 Clegg et al.||Source Title:||PLoS ONE||URI:||http://scholarbank.nus.edu.sg/handle/10635/124783||ISSN:||19326203||DOI:||10.1371/journal.pone.0038212|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
|2012-mdm2_ring_mutation_enhances_p53-published.pdf||489.94 kB||Adobe PDF|
checked on Oct 27, 2021
WEB OF SCIENCETM
checked on Oct 19, 2021
checked on Oct 28, 2021
checked on Oct 28, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.